See more : Saratoga Investment Corp 6.00% (SAT) Income Statement Analysis – Financial Results
Complete financial analysis of Notable Labs, Ltd. (NTBL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Notable Labs, Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Charlton Aria Acquisition Corporation (CHARU) Income Statement Analysis – Financial Results
- Everspring Industry Co., Ltd. (2390.TW) Income Statement Analysis – Financial Results
- Diamondback Energy, Inc. (FANG) Income Statement Analysis – Financial Results
- GlassBridge Enterprises, Inc. (GLAE) Income Statement Analysis – Financial Results
- Wärtsilä Oyj Abp (WRTBY) Income Statement Analysis – Financial Results
Notable Labs, Ltd. (NTBL)
About Notable Labs, Ltd.
Notable Labs, Ltd., a clinical-stage platform therapeutics company, engages in developing predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient is likely to respond to that specific therapeutic. Its PPMP is designed to identify and select clinically responsive patients prior to their treatment and thus fast-track clinical development in this patient population. The company's pipeline includes Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor for acute myeloid leukemia (AML), pediatric leukemia, and myelodysplastic syndromes indications; and Fosciclopirox, a pro-drug of ciclopirox for AML. Notable Labs, Ltd. is headquartered in Foster City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 310.00K | 8.00K | 285.00K | 922.00K | 562.00K | 585.00K | 13.86M | 0.00 | 0.00 |
| Cost of Revenue | 197.00K | 1.16M | 1.62M | 1.59M | 1.44M | 1.39M | 496.00K | 130.00K | 122.00K |
| Gross Profit | 113.00K | -1.15M | -1.34M | -666.00K | -879.00K | -806.00K | 13.37M | -130.00K | -122.00K |
| Gross Profit Ratio | 36.45% | -14,425.00% | -468.77% | -72.23% | -156.41% | -137.78% | 96.42% | 0.00% | 0.00% |
| Research & Development | 4.71M | 7.78M | 11.47M | 18.46M | 13.50M | 16.87M | 19.85M | 14.06M | 12.96M |
| General & Administrative | 10.06M | 5.16M | 5.73M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 10.06M | 5.16M | 5.73M | 5.36M | 5.71M | 5.55M | 6.36M | 3.79M | 3.64M |
| Other Expenses | -1.56M | -1.48M | 862.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 14.77M | 12.93M | 17.20M | 23.82M | 19.20M | 22.42M | 26.21M | 17.85M | 16.60M |
| Cost & Expenses | 14.97M | 12.93M | 17.20M | 25.41M | 20.64M | 23.81M | 26.71M | 17.98M | 16.72M |
| Interest Income | 0.00 | 0.00 | 0.00 | 363.00K | 870.00K | 908.00K | 335.00K | 263.00K | 100.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 105.00K | 184.00K | 37.00K | 27.00K | 12.00K | 16.00K |
| Depreciation & Amortization | 257.00K | 1.06M | 1.26M | 1.19M | 1.22M | 1.16M | 156.00K | 130.00K | 122.00K |
| EBITDA | -14.40M | -12.60M | -16.59M | -23.29M | -18.86M | -22.07M | -12.69M | -17.85M | -16.60M |
| EBITDA Ratio | -6,241.94% | -157,512.50% | -5,820.35% | -2,525.92% | -3,356.41% | -3,771.97% | -91.52% | 0.00% | 0.00% |
| Operating Income | -14.66M | -12.92M | -16.91M | -24.48M | -20.08M | -23.22M | -12.84M | -17.98M | -16.72M |
| Operating Income Ratio | -4,728.06% | -161,550.00% | -5,934.74% | -2,655.42% | -3,573.31% | -3,969.57% | -92.64% | 0.00% | 0.00% |
| Total Other Income/Expenses | 3.39M | -1.48M | 862.00K | 258.00K | 686.00K | 2.76M | 2.71M | 1.97M | 1.83M |
| Income Before Tax | -11.26M | -14.41M | -16.05M | -24.23M | -19.40M | -20.46M | -10.14M | -16.00M | -14.89M |
| Income Before Tax Ratio | -3,633.55% | -180,087.50% | -5,632.28% | -2,627.44% | -3,451.25% | -3,497.09% | -73.12% | 0.00% | 0.00% |
| Income Tax Expense | -4.95M | 94.52K | 89.44K | -1.00 | -1.00 | -1.00 | 0.00 | -1.00 | 0.00 |
| Net Income | -11.26M | -14.41M | -16.05M | -24.23M | -19.40M | -20.46M | -10.14M | -16.00M | -14.89M |
| Net Income Ratio | -3,633.55% | -180,087.50% | -5,632.28% | -2,627.44% | -3,451.25% | -3,497.09% | -73.12% | 0.00% | 0.00% |
| EPS | -5.03 | -6.50 | -9.28 | -19.42 | -18.92 | -0.62 | -0.37 | -0.64 | -0.73 |
| EPS Diluted | -5.03 | -6.50 | -9.28 | -19.42 | -18.92 | -0.62 | -0.37 | -0.64 | -0.73 |
| Weighted Avg Shares Out | 2.24M | 2.22M | 1.73M | 1.25M | 1.03M | 32.97M | 27.40M | 24.97M | 20.31M |
| Weighted Avg Shares Out (Dil) | 2.24M | 2.22M | 1.73M | 1.25M | 1.03M | 32.97M | 27.40M | 24.97M | 20.31M |
Notable Advances Volasertib Phase 2 Program Utilizing Proprietary Predictive Precision Medicine Platform-Guided Enrollment
Notable Reports Predictive Precision Medicine Platform (PPMP) Accurately Predicted Fosciclopirox Trial Outcome
Notable Labs Donates $60,000 to MDS Foundation to Accelerate Progress for Patients with Myelodysplastic Syndromes
Notable Labs Funds Myelodysplastic Syndromes Foundation with $60,000 Grant
Notable Labs to Participate in JMP Securities Hematology and Oncology Summit
Notable Labs Announces Filing of Form 10-Q for Third Quarter 2023
Source: https://incomestatements.info
Category: Stock Reports